Suche
Mein Konto
Revolutionary therapy: Nurexone on the way to the elite
Will the news about the exosome startup trigger the next hype? Find out how Nurexone is revolutionizing the industry and what impact this could have on the market. #Exosomes #RevolutionaryTherapy
Revolutionary therapy: Nurexone on the way to the elite
The well-known development of Nurexone Biologic Inc.*, particularly in connection with Dr. Lior Shaltiel, the company's CEO, who will give a landmark presentation at the Exosomes of Europe conference in London, has caused a stir. The planned launch of the revolutionary spinal therapy ExoPTEN at this prestigious event highlights the company's position in a market dominated by big names such as Abbvie and Evox Therapeutics.
Compared to competitors such as Evox Therapeutics, Nurexone Biologic stands out for its innovative approach. While Evox uses gene-modified exosomes, Nurexone relies on loading untreated exosomes, which could enable the development of nanomedicines for various clinical indications. This strategy has attracted the interest of well-known investors, which is a clear sign of the company's potential.
The recently announced large-scale animal trials for ExoPTEN therapy in spinal cord injury mark a significant milestone for Nurexone. These tests, which will be conducted on 100 rats and evaluate different dosages, will ultimately lead to the submission of an Investigational New Drug application to the FDA. The promising results of previous studies suggest that ExoPTEN nasal spray has the potential to restore remarkable function in neurological diseases such as paraplegia.